- Home
- PRLD vs CUE Comparison
PRLD vs CUE Comparison
Compare PRLD & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- CUE
- Stock Information
- Founded
- PRLD 2016
- CUE 2014
- Country
- PRLD United States
- CUE United States
- Employees
- PRLD N/A
- CUE N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- PRLD Health Care
- CUE Health Care
- Exchange
- PRLD Nasdaq
- CUE Nasdaq
- Market Cap
- PRLD 50.1M
- CUE 58.9M
- IPO Year
- PRLD 2020
- CUE 2018
- Fundamental
- Price
- PRLD $0.78
- CUE $0.78
- Analyst Decision
- PRLD Strong Buy
- CUE Strong Buy
- Analyst Count
- PRLD 2
- CUE 3
- Target Price
- PRLD $4.50
- CUE $3.00
- AVG Volume (30 Days)
- PRLD 110.2K
- CUE 161.8K
- Earning Date
- PRLD 05-06-2025
- CUE 05-20-2025
- Dividend Yield
- PRLD N/A
- CUE N/A
- EPS Growth
- PRLD N/A
- CUE N/A
- EPS
- PRLD N/A
- CUE N/A
- Revenue
- PRLD $7,000,000.00
- CUE $9,287,000.00
- Revenue This Year
- PRLD N/A
- CUE N/A
- Revenue Next Year
- PRLD N/A
- CUE $25.99
- P/E Ratio
- PRLD N/A
- CUE N/A
- Revenue Growth
- PRLD N/A
- CUE 69.16
- 52 Week Low
- PRLD $0.61
- CUE $0.45
- 52 Week High
- PRLD $6.80
- CUE $2.26
- Technical
- Relative Strength Index (RSI)
- PRLD 46.96
- CUE 46.03
- Support Level
- PRLD $0.73
- CUE $0.71
- Resistance Level
- PRLD $1.00
- CUE $0.78
- Average True Range (ATR)
- PRLD 0.09
- CUE 0.06
- MACD
- PRLD -0.01
- CUE 0.01
- Stochastic Oscillator
- PRLD 18.96
- CUE 46.11
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.